KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Treasury Shares: 2009-2024

Historic Treasury Shares for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $1.4 million.

  • Halozyme Therapeutics' Treasury Shares rose 22.77% to $1.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.4 million, marking a year-over-year increase of 22.77%. This contributed to the annual value of $1.4 million for FY2024, which is 22.77% up from last year.
  • According to the latest figures from FY2024, Halozyme Therapeutics' Treasury Shares is $1.4 million, which was up 22.77% from $1.1 million recorded in FY2023.
  • In the past 5 years, Halozyme Therapeutics' Treasury Shares ranged from a high of $6.5 million in FY2020 and a low of $1.1 million during FY2023.
  • Its 3-year average for Treasury Shares is $2.3 million, with a median of $1.4 million in 2024.
  • As far as peak fluctuations go, Halozyme Therapeutics' Treasury Shares plummeted by 74.68% in 2023, and later grew by 22.77% in 2024.
  • Halozyme Therapeutics' Treasury Shares (Yearly) stood at $6.5 million in 2020, then tumbled by 40.00% to $3.9 million in 2021, then increased by 15.38% to $4.5 million in 2022, then plummeted by 74.68% to $1.1 million in 2023, then increased by 22.77% to $1.4 million in 2024.